

Supplemental Table S2

Pathway Enrichment for 11 Male and Female Rat Tissue Signature Lists

| Pathway name | Sex.Tissue | | | | | | | | | | | | |
|---|-------------------------------|------|----------------|---------|----|-----|---------|-----|-----|----------|-----|------|---------------|
| | Number of genes in input list | | | | | | | | | | | | |
| | 230 | 4059 | 11 Male & fem. | Tissues | 79 | 172 | M.Heart | 151 | 725 | M.Kidney | 191 | 1298 | Fem 5 tissues |
| Pathways in cancer | 45 | 32 | 3 | 7 | 6 | 13 | 1 | 2 | 17 | 6 | 3 | 1 | 3 |
| Protein processing in endoplasmic reticulum | 39 | 38 | 3 | 4 | 1 | 22 | 5 | 4 | 3 | 1 | | | 1 |
| HTLV-I infection | 39 | 31 | | 8 | 3 | 14 | 3 | 2 | 10 | 4 | 2 | | 1 |
| RNA transport | 39 | 31 | 1 | 8 | | 17 | 3 | 6 | 11 | 4 | | 1 | 2 |
| Transcriptional misregulation in cancers | 31 | 26 | 1 | 8 | 6 | 7 | 4 | 3 | 12 | 6 | 3 | 1 | |
| Herpes simplex infection | 30 | 23 | 2 | 10 | 3 | 7 | 2 | 1 | 9 | 3 | 1 | | 2 |
| Lysosome | 29 | 27 | 1 | 5 | 4 | 16 | 2 | 2 | 5 | 1 | | | 1 |
| Ribosome | 29 | 27 | 2 | 5 | | 1 | | 20 | 4 | 1 | 1 | 2 | |
| Endocytosis | 29 | 26 | 1 | 4 | 8 | 11 | 1 | 3 | 5 | 2 | | | 3 |
| Phagosome | 28 | 27 | 1 | 6 | 6 | 12 | | 2 | 7 | | 3 | | 4 |
| MAPK signaling pathway | 28 | 21 | 1 | 7 | 3 | 7 | 1 | 2 | 8 | 3 | | | 1 |
| Spliceosome | 27 | 17 | | 8 | 1 | 1 | 2 | 7 | 12 | 6 | 1 | | 1 |
| Regulation of actin cytoskeleton | 26 | 24 | 1 | 6 | 6 | 9 | | 3 | 5 | 3 | | 1 | 1 |
| Alzheimer's disease | 26 | 22 | 2 | 4 | | 7 | | 10 | 5 | | | | 2 |
| Huntington's disease | 26 | 22 | 1 | 6 | | 2 | | 14 | 5 | 1 | | 1 | 2 |
| Purine metabolism | 26 | 22 | 1 | 6 | 2 | 4 | 2 | 6 | 7 | 2 | | | 5 |
| Focal adhesion | 26 | 21 | 2 | 2 | 7 | 8 | | 3 | 9 | 3 | | 2 | 4 |
| Chemokine signalling pathway | 24 | 23 | 3 | 4 | 6 | 9 | 1 | 1 | 4 | | | | 2 |
| Pyrimidine metabolism | 24 | 20 | 1 | 6 | 1 | 6 | 1 | 5 | 6 | 1 | | 1 | 3 |
| Tuberculosis | 24 | 20 | | 6 | 6 | 9 | 1 | | 9 | 1 | 1 | | 7 |
| Influenza A | 23 | 21 | 1 | 5 | 2 | 11 | 1 | 3 | 5 | 1 | 2 | | 2 |
| Oxidative phosphorylation | 23 | 20 | 1 | 4 | | 5 | | 11 | 5 | | 1 | | 1 |
| Leukocyte transendothelial migration | 22 | 18 | 2 | 1 | 7 | 8 | | 1 | 6 | 4 | 1 | | 1 |
| Cytokine-cytokine receptor interaction | 21 | 19 | 1 | 6 | 7 | 6 | | | 4 | 3 | | | 1 |
| Osteoclast differentiation | 21 | 18 | 1 | 2 | 6 | 10 | 1 | | 5 | 1 | | | 1 |
| Cell adhesion molecules (CAMs) | 20 | 14 | 2 | 3 | 4 | 6 | 1 | | 7 | 3 | 1 | | 1 |
| Insulin signalling pathway | 19 | 13 | | 2 | 3 | 6 | 2 | | 6 | 2 | | | 4 |
| mRNA surveillance pathway | 19 | 13 | 1 | 4 | | 5 | 2 | 4 | 8 | 4 | | | 2 |

| | | | | | | | | | | | | | | |
|--|----|----|---|---|----|----|---|---|---|---|---|---|---|---|
| Ribosome biogenesis in eukaryotes | 19 | 13 | | 4 | 1 | 6 | | 4 | 7 | 1 | | 1 | 5 | |
| Wnt signaling pathway | 18 | 14 | 1 | 3 | 2 | 6 | 1 | 1 | 4 | 2 | | | | 2 |
| Neuroactive ligand-receptor interaction | 18 | 12 | 1 | | 3 | 6 | 1 | 1 | 7 | 3 | 3 | | | 2 |
| RNA degradation | 18 | 12 | 1 | 2 | | 4 | 2 | 4 | 7 | 1 | 1 | | 2 | 4 |
| Tight junction | 18 | 12 | 1 | 2 | 2 | 6 | | 1 | 9 | 6 | | | 1 | 2 |
| Calcium signaling pathway | 17 | 16 | 1 | 4 | 3 | 7 | | | 4 | 2 | 1 | | | 1 |
| Parkinson's disease | 17 | 15 | 1 | 3 | | 3 | | 9 | 2 | | | | 1 | 1 |
| Ubiquitin mediated proteolysis | 17 | 12 | | | 12 | 1 | | 7 | 3 | 1 | | 1 | 2 | |
| Measles | 16 | 16 | | 3 | 3 | 8 | 1 | | 4 | 2 | | | | 2 |
| Hepatitis C | 16 | 11 | | 1 | 2 | 7 | 1 | | 6 | 1 | | 2 | 3 | |
| Cell cycle | 16 | 10 | | 2 | | 9 | 1 | | 4 | 1 | | 2 | 1 | |
| Phosphatidylinositol signaling system | 16 | 10 | | 1 | 3 | 6 | | 2 | 5 | 3 | | 1 | 1 | |
| Fc gamma R-mediated phagocytosis | 15 | 16 | 1 | 1 | 5 | 9 | | 1 | | | | | | |
| Natural killer cell mediated cytotoxicity | 15 | 14 | 1 | 2 | 6 | 4 | | 1 | 4 | 1 | 1 | | | 2 |
| Systemic lupus erythematosus | 15 | 14 | | 6 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | | | 1 |
| Dopaminergic synapse | 15 | 12 | 1 | 2 | 2 | 6 | 1 | | 3 | 1 | | 1 | 1 | |
| Antigen processing and presentation | 15 | 11 | 1 | 4 | 2 | 2 | 1 | 1 | 4 | 1 | 1 | | | 2 |
| Small cell lung cancer | 15 | 11 | 1 | 1 | 2 | 5 | 1 | 1 | 5 | | 1 | 1 | 1 | 2 |
| Apoptosis | 15 | 10 | | 2 | 2 | 5 | 1 | | 8 | 2 | 2 | | 1 | 3 |
| Toxoplasmosis | 15 | 10 | | 2 | 2 | 6 | 1 | | 6 | | 2 | | 1 | 3 |
| Rheumatoid arthritis | 14 | 12 | 1 | 1 | 3 | 5 | | 1 | 5 | 1 | 1 | | | 3 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 14 | 11 | | 5 | 1 | 5 | | | 3 | 2 | | | | 1 |
| Jak-STAT signaling pathway | 14 | 11 | | 2 | 3 | 5 | 1 | | 3 | 2 | 1 | | | |
| Chagas disease (American trypanosomiasis) | 14 | 10 | | 3 | 3 | 3 | 1 | | 5 | | 1 | 1 | 4 | |
| Inositol phosphate metabolism | 14 | 9 | | 1 | 1 | 4 | | 4 | 4 | 2 | | | 1 | 1 |
| Serotonergic synapse | 14 | 8 | 2 | 2 | 1 | 3 | | | 6 | 1 | 2 | | 1 | 3 |
| N-Glycan biosynthesis | 13 | 13 | 1 | 1 | | 11 | 1 | 1 | | | | | | |
| Dilated cardiomyopathy (DCM) | 13 | 12 | | 7 | | 3 | | | 4 | 2 | 1 | | | 1 |
| Adherens junction | 13 | 11 | | | 2 | 9 | | | 5 | 3 | | | | 2 |
| Glycerophospholipid metabolism | 13 | 11 | 2 | 2 | 2 | 3 | 1 | 3 | 3 | 1 | | | | 2 |
| T cell receptor signaling pathway | 13 | 10 | 1 | | 4 | 4 | 1 | 1 | 5 | 1 | | 1 | 3 | |
| Complement and coagulation cascades | 13 | 8 | | 3 | 1 | 1 | 2 | 2 | 4 | 2 | 1 | | | 2 |
| Protein digestion and absorption | 13 | 8 | | 3 | 1 | 4 | | | 5 | | 2 | 2 | | 1 |
| Adipocytokine signaling pathway | 13 | 6 | | | 1 | 4 | 1 | | 9 | 1 | 1 | | 3 | 4 |
| Hematopoietic cell lineage | 12 | 12 | 1 | 2 | 5 | 5 | | | 4 | 1 | 1 | | | 2 |
| Synaptic vesicle cycle | 12 | 12 | | | 1 | 10 | | 1 | 2 | | | | | 2 |
| Aminoacyl-tRNA biosynthesis | 12 | 11 | | 1 | | 5 | 7 | | 2 | | | | 1 | 2 |
| Amoebiasis | 12 | 11 | 1 | 3 | 1 | 4 | 1 | | 3 | | | 1 | | 2 |
| Pertussis | 12 | 11 | | 3 | 3 | 3 | 1 | 1 | 3 | | 2 | | | 2 |
| Salmonella infection | 12 | 11 | | 4 | 1 | 4 | 2 | | 3 | | 1 | 1 | | 1 |
| Toll-like receptor signaling pathway | 12 | 11 | 1 | 3 | 2 | 4 | 1 | | 2 | | | 1 | 1 | |
| Axon guidance | 12 | 10 | 1 | | 3 | 5 | | 3 | 3 | 1 | | 1 | | 1 |
| Bacterial invasion of epithelial cells | 12 | 10 | 1 | 1 | 1 | 6 | 1 | 1 | 3 | 2 | | | | 1 |

| | | | | | | | | | | | | | |
|---|----|----|---|---|---|---|---|---|---|---|---|---|---|
| Viral myocarditis | 12 | 10 | | 3 | 2 | 4 | | 4 | 1 | 1 | 1 | | 1 |
| Cardiac muscle contraction | 12 | 9 | 1 | 4 | 1 | 1 | | 2 | 4 | 1 | 2 | | 1 |
| Vascular smooth muscle contraction | 12 | 9 | 1 | 3 | 2 | 1 | | 1 | 5 | 2 | 1 | | 2 |
| ECM-receptor interaction | 12 | 8 | 1 | 2 | 2 | 3 | 1 | | 5 | | 2 | 2 | 1 |
| Hypertrophic cardiomyopathy (HCM) | 12 | 8 | | 6 | | 2 | | | 5 | 2 | 1 | | 2 |
| GnRH signaling pathway | 11 | 11 | 2 | 4 | 1 | 3 | | | 2 | | | | 2 |
| Neurotrophin signaling pathway | 11 | 11 | 1 | 1 | 3 | 6 | 1 | | 1 | | | | 1 |
| Circadian rhythm - mammal | 11 | 9 | 1 | | 2 | 3 | 4 | | 5 | 3 | | | 2 |
| Cytosolic DNA-sensing pathway | 11 | 9 | | 3 | 1 | 3 | 1 | 1 | 4 | | 1 | 1 | 2 |
| Mineral absorption | 11 | 9 | | 5 | 1 | 2 | 1 | | 3 | 1 | 1 | | 1 |
| Progesterone-mediated oocyte maturation | 11 | 9 | | 1 | 1 | 5 | 2 | | 2 | | | | 2 |
| Staphylococcus aureus infection | 11 | 9 | | 4 | 2 | 2 | 1 | | 3 | 1 | 2 | | 1 |
| Chronic myeloid leukemia | 11 | 7 | | | 1 | 5 | 1 | | 5 | 1 | 2 | | 1 |
| p53 signaling pathway | 11 | 7 | | 1 | | 5 | 4 | | 2 | 1 | | | 1 |
| PPAR signaling pathway | 11 | 5 | | 1 | 2 | 2 | 1 | | 8 | | 1 | 2 | 1 |
| B cell receptor signaling pathway | 10 | 10 | | | 3 | 4 | 1 | 1 | 2 | | | 1 | 1 |
| Leishmaniasis | 10 | 10 | | 3 | 2 | 4 | 1 | | 2 | | 1 | | 1 |
| Bile secretion | 10 | 9 | 1 | 2 | 1 | 4 | | | 2 | | 1 | | 1 |
| Oocyte meiosis | 10 | 9 | 1 | 1 | 1 | 5 | | | 2 | | | 1 | 1 |
| Acute myeloid leukemia | 10 | 8 | | 1 | 2 | 4 | 1 | | 3 | | 1 | 1 | 1 |
| Cholinergic synapse | 10 | 8 | | 2 | 3 | 2 | | | 4 | 1 | | 1 | 2 |
| mTOR signaling pathway | 10 | 8 | 2 | 1 | 1 | 4 | | | 3 | 2 | | | 1 |
| Porphyrin and chlorophyll metabolism | 10 | 8 | | 4 | 2 | | 1 | 1 | 3 | 1 | 1 | 1 | |
| Prostate cancer | 10 | 8 | 1 | | 2 | 4 | 1 | | 3 | 1 | | | 1 |
| Pancreatic cancer | 10 | 7 | 1 | | 2 | 3 | 1 | | 5 | 2 | 1 | | 1 |
| Basal transcription factors | 10 | 6 | 2 | 1 | 1 | 1 | 1 | | 4 | 1 | | 1 | 2 |
| Drug metabolism - other enzymes | 10 | 5 | | 3 | 1 | 1 | | | 5 | 3 | | | 2 |
| Malaria | 10 | 5 | 1 | | 4 | | 1 | | 7 | | 3 | 4 | 3 |
| Fc epsilon RI signaling pathway | 9 | 10 | 1 | | 5 | 3 | | | 1 | | | | 1 |
| Gap junction | 9 | 10 | 1 | 2 | 3 | 3 | | | 1 | | | | 1 |
| Endocrine and other factor-regulated calcium reabsorption | 9 | 9 | | 4 | 2 | 2 | | | 1 | | 1 | | |
| Salivary secretion | 9 | 9 | | 1 | 3 | 4 | 1 | | 2 | 1 | 1 | | |
| GABAergic synapse | 9 | 8 | | 2 | | 3 | 1 | 1 | 3 | | | 1 | 2 |
| RNA polymerase | 9 | 8 | | 4 | | 1 | | 3 | 2 | | | | 2 |
| VEGF signaling pathway | 9 | 8 | | | 2 | 5 | | 2 | 2 | 1 | | | 1 |
| Glutamatergic synapse | 9 | 7 | | 2 | | 2 | 1 | 1 | 3 | 1 | | 1 | 1 |
| Legionellosis | 9 | 7 | | 2 | | 3 | 2 | | 4 | | 1 | 1 | 2 |
| Prion diseases | 9 | 7 | | 2 | 3 | | 2 | | 3 | | 1 | 1 | 2 |
| TGF-beta signaling pathway | 9 | 6 | 1 | 1 | 3 | 1 | | | 4 | 2 | | | 2 |
| Cysteine and methionine metabolism | 9 | 5 | | 3 | 1 | 1 | | | 4 | 1 | | 1 | 2 |
| Renal cell carcinoma | 9 | 5 | 1 | | 1 | 3 | | | 5 | 2 | 1 | | 1 |
| Glutathione metabolism | 8 | 8 | | 2 | | 3 | 2 | 2 | 1 | | | | 1 |
| Proteasome | 8 | 8 | | 3 | | 3 | | 3 | | | | | |
| Amino sugar and nucleotide sugar metabolism | 8 | 7 | 1 | | 1 | 4 | | 1 | 1 | | | | 1 |
| Gastric acid secretion | 8 | 7 | | 1 | 2 | 2 | 1 | | 2 | | 2 | | |
| RIG-I-like receptor signaling pathway | 8 | 7 | | 1 | 1 | 3 | 2 | | 2 | | | 1 | 1 |
| Notch signaling pathway | 8 | 6 | 1 | | | 4 | | 1 | 3 | 2 | | | 1 |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valine, leucine and isoleucine degradation | 8 | 6 | | 1 | | | 5 | 2 | | | | 2 |
| Endometrial cancer | 8 | 5 | | 1 | 4 | | | 3 | 3 | | | |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | 8 | 4 | | | 3 | | 1 | 4 | 1 | 1 | 1 | 1 |
| Protein export | 7 | 8 | 1 | | 3 | 2 | 1 | | | | | |
| Butanoate metabolism | 7 | 7 | | 2 | | | 5 | | | | | |
| Glioma | 7 | 7 | | 3 | 4 | | | | | | | |
| Melanogenesis | 7 | 7 | | 3 | 1 | 2 | | 1 | 1 | | | |
| Pancreatic secretion | 7 | 7 | | 2 | 5 | | | 2 | 1 | 1 | | |
| Collecting duct acid secretion | 7 | 6 | | | 5 | | 1 | 3 | | 1 | | 2 |
| Colorectal cancer | 7 | 6 | | 2 | 3 | | | 2 | 2 | | | |
| Aldosterone-regulated sodium reabsorption | 7 | 5 | | 3 | 3 | | | 1 | | 1 | | |
| Arachidonic acid metabolism | 7 | 5 | 1 | 2 | 1 | 1 | | 1 | 3 | | 1 | 1 |
| Bladder cancer | 7 | 5 | 1 | 2 | | 2 | | | 3 | 2 | | 1 |
| Hedgehog signaling pathway | 7 | 5 | | 3 | 1 | 1 | | 2 | | | 1 | 1 |
| Amyotrophic lateral sclerosis (ALS) | 7 | 4 | | | 2 | | 2 | 4 | | 2 | 1 | 1 |
| Metabolism of xenobiotics by cytochrome P450 | 7 | 4 | 1 | | 2 | 1 | 1 | 4 | 2 | | | 3 |
| Melanoma | 6 | 6 | | 2 | 4 | | | | | | | |
| Non-small cell lung cancer | 6 | 6 | | 2 | 4 | | | | | | | |
| Sphingolipid metabolism | 6 | 6 | | 2 | 4 | | 1 | 1 | | | | 1 |
| ErbB signaling pathway | 6 | 5 | | 2 | 3 | | | 2 | 1 | | | 1 |
| Regulation of autophagy | 6 | 5 | | | 4 | | 1 | 1 | | | | 1 |
| Steroid biosynthesis | 6 | 5 | | | 5 | | | 1 | 1 | | | |
| Vasopressin-regulated water reabsorption | 6 | 5 | 1 | | 2 | | 1 | 2 | 1 | 1 | | |
| ABC transporters | 6 | 4 | | 1 | 3 | | | 2 | | | 2 | |
| Type I diabetes mellitus | 6 | 4 | | 3 | 1 | | | 2 | | 1 | | 1 |
| Drug metabolism - cytochrome P450 | 6 | 3 | | | 2 | 1 | 1 | 4 | 2 | | | 3 |
| Other glycan degradation | 5 | 5 | 2 | | 4 | | | 2 | | 1 | | 1 |
| SNARE interactions in vesicular transport | 5 | 5 | | 1 | 1 | 1 | | 3 | | | | |
| NOD-like receptor signaling pathway | 5 | 4 | | | 1 | 2 | 1 | | 3 | | 1 | 1 |
| Primary immunodeficiency | 5 | 4 | 1 | | 1 | 2 | | | 2 | | 1 | 1 |
| African trypanosomiasis | 5 | 3 | | | 1 | 1 | | | 4 | | 1 | 3 |
| Thyroid cancer | 4 | 4 | | | 4 | | 1 | 1 | | | | 1 |
| Glycolysis / Gluconeogenesis | 4 | 3 | | 1 | 1 | | 1 | 1 | | | | 1 |
| Synthesis and degradation of ketone bodies | 3 | 3 | | | | | 3 | | | | | |

Only Pathways with 3 or more affected genes per

signature list are shown